US 12,178,857 B2Granted

Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury

AssigneeAM-Pharma B.V.

InventorsRoelof Peter Pickkers, Ravindra Lall Mehta, Patrick Thomas Murray, Michael Joannidis, Erik Jan Van Den Berg, Jacques Salomon Robert Arend

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The present disclosure relates to the use of alkaline phosphatases, and in particular improved alkaline phosphatases such as RecAP, for the prevention, treatment, cure, or amelioration of the symptoms of acute kidney injury caused, e.g., by sepsis. The application relates to methods of preserving renal function renal function, shortening the duration of renal replacement therapy, increasing the creatinine clearance, decreasing the risk of death in subjects with sepsis-associate acute kidney injury (SA-AKI) or at risk of SA-AKI.

Claims13

Dependent claims

A method to treat sepsis-associated acute kidney disease injury (SA-AKI) in a subject in need thereof comprising administering an effective amount of alkaline phosphatase (AP) to the subject, wherein

(i) the subject has an ECC (endogenous creatinine clearance) rate 15-60 ml/min prior to the treatment with AP or an eGFR (estimated glomerular filtration rate) 15-60 ml/min prior to the treatment with AP,
(ii) the AP is administered in at least one 500 U/kg to 2,000 U/kg dose, and
(iii) the administration of the AP results in an increase in renal function,
wherein the AP is a chimeric AP having 100% sequence identity to the amino acid sequence of SEQ ID NO:
1.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/979,117Filed 8 Mar 2019 · us provisional application
Priority: 8 Mar 2018
Published: US 2020/0397870 A124 Dec 2020
Granted: 31 Dec 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 38/43
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: enzymes; Proenzymes; Derivatives thereof
A61K 38/465
Hydrolases: acting on ester bonds , e.g. lipases, ribonucleases
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61P 13/12
Drugs for disorders of the urinary system: of the kidneys

Family

Application62/640,494Us provisional application · filed 8 Mar 2018
US 2020/0397870 A1Pre-grant publication · published 24 Dec 2020
US 12,178,857 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key